Home › Therapeutic areas › Neurology › Multiple Sclerosis
Multiple Sclerosis (17 companies)
Companies with an active program in Multiple Sclerosis.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ALMS | Alumis | DermatologyImmunology+1 | 1 | Phase 3 | $628M | 5 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 1 | Approved | $290M | 12 |
| CLNN | Clene | Neurology Rare | 1 | NDA Submitted | $46.4M | 5 |
| CTNM | Contineum Therapeutics | NeurologyRespiratory Rare | 1 | Phase 2 | $375M | 4 |
| HRMY | Harmony Biosciences | MetabolicNeurology Rare | 1 | Approved | $1.94B | 17 |
| IMUX | Immunic | GI/HepatologyNeurology | 2 | Phase 3 | $116M | 4 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | 1 | NDA Submitted | $297M | 6 |
| NRXP | NRX Pharmaceuticals | Neurology Rare | 1 | Approved | $109M | 11 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 1 | Phase 3 | $1.56B | 13 |
| OCS | Oculis Holding | NeurologyOphthalmology Rare | 1 | Phase 3 | $418M | 5 |
| DTIL | Precision Biosciences | Infectious DiseaseMetabolic+1 Rare | 1 | Phase 1 | $197M | 5 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyImmunology+2 Rare | 1 | Phase 2 | $4.8M | 7 |
| TGTX | Tg Therapeutics | Neurology Rare | 3 | Approved | $9.48B | 6 |
| TLSA | Tiziana Life Sciences | ImmunologyNeurology Rare | 1 | Phase 2 | $83.2M | 5 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | $230M | 27 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.59B | 28 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 3 | NDA Submitted | $1.88B | 11 |
No companies match.